% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kayser:131055,
      author       = {S. Kayser and M. Feszler$^*$ and J. Krzykalla$^*$ and M.
                      Schick$^*$ and M. Kramer and A. Benner$^*$ and F. Thol and
                      U. Platzbecker and C. Müller-Tidow and A. D. Ho and G.
                      Ehninger and M. Heuser and R. F. Schlenk and C. Thiede and
                      C. Röllig and A. Krämer$^*$},
      title        = {{C}linical impact of {KMT}2{C} and {SPRY}4 expression
                      levels in intensively treated younger adult acute myeloid
                      leukemia patients.},
      journal      = {European journal of haematology},
      volume       = {99},
      number       = {6},
      issn         = {0902-4441},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2017-06122},
      pages        = {544 - 552},
      year         = {2017},
      abstract     = {To evaluate the prognostic impact of gene expression levels
                      (ELs) of two tumor suppressor genes, sprouty 4 (SPRY4,
                      located on 5q) and lysine methyltransferase 2C (KMT2C,
                      located on 7q) in correlation with clinical characteristics
                      and genetic abnormalities assessed at initial diagnosis in
                      acute myeloid leukemia (AML).Gene expression levels were
                      measured on cDNA by RT-qPCR from diagnostic bone marrow
                      samples of 275 intensively treated adult AML patients
                      (median age, 48 years).KMT2C ELs were significantly lower
                      in abn7q/-7 (P = .001), whereas SPRY4 ELs were not
                      associated with abn5q/-5. Higher KMT2C and SPRY4 ELs were
                      significantly associated with lower genetic risk groups as
                      defined by the European LeukemiaNet classification.
                      Additionally, KMT2C ELs were lower in cytogenetically normal
                      patients with DNMT3A (P = .01) or FLT3-ITD mutations
                      (P = .05). KMT2C ELs were not associated with prognosis,
                      whereas higher SPRY4 ELs showed a favorable impact on
                      event-free (EFS, P = .01), relapse-free (RFS, P = .01)
                      and in-trend on overall survival (P = .06) for
                      cytogenetically abnormal patients, which was confirmed in
                      multivariable analysis for EFS (HR, 0.84; $95\%-CI,$
                      0.73-0.97; P = .02) and RFS (HR, 0.85; $95\%-CI,$
                      0.73-0.98; P = .02).Our data indicate that KMT2C ELs are
                      associated with specific genetic features and that SPRY4 ELs
                      may add prognostic information.},
      cin          = {G330 / C060 / W110},
      ddc          = {610},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)W110-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28940816},
      doi          = {10.1111/ejh.12972},
      url          = {https://inrepo02.dkfz.de/record/131055},
}